Sep 12, 2017

Cystic fibrosis (CF) is caused by mutations within the cystic fibrosis transmembrane conductance regulator (CFTR) gene, that code for the CFTR protein and it’s conjointly called chromosome recessive sickness.  As a multisystem condition, CF patients show great heterogeneity in presenting clinical symptoms.  CF mainly affects the respiratory and gastrointestinal tracts.  Mostly three classes of drugs have been used for the treatment in CF patients: inhaled antibiotics for bacterial and fungal respiratory infections, mucolytic drugs for mucociliary clearance of the airways, and pancreatic enzyme replacement therapies (PERTs) for treatment of CF induced exocrine pancreatic insufficiency (EPI).  During the last five years, new category of medication was embarked on the market, specifically treating the underlying cause of Cystic fibrosis.  These CFTR modulators help restore function of the insufficient CFTR protein.  This growth will be driven primarily by the highly anticipated arrival of the CFTR modulator, Vertex Pharmaceuticals’ ivacaftor/tezacaftor.  Arikace one more drug for Cystic fibrosis is also estimated to launch throughout the forecast period however is not expected to drive CF market growth as much as the CFTR modulator, since it will be competing with other inhaled antibiotics.

Global (7MM) sales for the cystic fibrosis (CF) market are forecasted by GlobalData to grow from $2.1B in 2015 to $7.6B in 2025.  The bulk of sales are expected to come from the United States, which will represent 68% of the market by 2025.  The sales growth throughout the 2015–2025 forecast periods will be mainly determined by the launches of Vertex’s cystic fibrosis transmembrane conductance regulator (CFTR) modulator ivacaftor/tezacaftor.

The CFTR modulator drug category is expected to grow from 43.3% of total CF drug sales in 2015 to 81.2% of total CF drug sales in 2025.  Vertex Pharmaceuticals highly prescribed drug will still continue to dominate the CF drug space as it has two marketed CFTR modulators and is predicted to launch third CFTR modulator throughout this forecast period, fulfilling some of the major unmet needs of the CF population.

Inhaled antibiotics, mucolytic drugs, and PERTs have been the keystone of CF treatment.  The introduction of CFTR modulators has contributed to higher treatment of CF patients; nevertheless, the overall life probability in CF patients is still 20–25 years less than in the healthy population.  Therefore, there are significantly high unmet needs within the indication.

For more HealthCare Industry report visit WWW.MarketsandReports.Com/MarketReports

About is a syndicated report platform with wide variety of industry reports from reputed industry publishers. is promoted by DART Consulting. lists variety of reports at the best price with seasonal discounts and promotion codes.

Contact us:

Direct : + 91-80- 4224 7136, 953-807- 6063



Share :